Company Directory

Small molecule drug discovery targeting rare genetic diseases and oncology

Tay Therapeutics is a drug discovery company developing targeted small molecule therapies for rare genetic diseases and cancer. Its platform uses stop codon read-through technology to restore production of functional proteins disrupted by premature stop codon mutations, with programmes targeting oncology, cystic fibrosis, Duchenne muscular dystrophy, and epidermolysis bullosa. The company previously discovered and out-licensed two BET inhibitor programmes to VYNE Therapeutics, which are advancing in clinical trials for immuno-inflammatory conditions.

Single-workflow sequencing technology capturing genetic and epigenetic data

biomodal is a Cambridge-based life sciences technology company developing multiomics sequencing solutions that simultaneously capture genetic and epigenetic information from a single DNA sample. Its multiomics platform detects the canonical four DNA bases alongside 5-methylcytosine and 5-hydroxymethylcytosine modifications at single-base resolution, without requiring additional hardware or bisulfite treatment. The technology is compatible with existing sequencing infrastructure and targets applications in oncology, neurodegenerative disease research, and liquid biopsy diagnostics.

Non-invasive skin epigenomics platform for clinical and cosmetic research

Mitra Bio is a contract research organisation providing a non-invasive skin epigenomics platform to pharmaceutical and cosmetic companies conducting clinical trials on dermatological and age-reversal interventions. Using tape-strip skin sampling combined with whole-genome DNA methylation sequencing and bioinformatic analysis, the company generates biological age assessments and predictive biomarkers to evaluate treatment efficacy and guide compound development. Mitra Bio also collaborates with clinical partners on epigenetic approaches to melanoma screening.

Gene editing tools, cell lines and genomic reagents for life science research

Horizon Discovery is a Cambridge-based life sciences company supplying gene editing and gene modulation tools, services, and engineered cell lines to pharmaceutical, biotechnology, and academic customers. Its portfolio includes CRISPR and RNAi reagents, isogenic cell line pairs modelling disease-associated mutations, RNA synthesis, functional genomic screening services, and molecular reference standards for NGS-based diagnostics. The Cambridge site operates as a centre of excellence for genomic research within parent company Revvity.

Clinical skin microbiome testing and multi-omic ingredient analysis platform

Sequential Skin is a biotechnology company providing non-invasive clinical microbiome testing and multi-omic analysis services to the personal care and pharmaceutical industries. Using patch-based sampling and next-generation sequencing, the company quantifies how ingredients and formulations affect the skin microbiome and host biomarkers. Its proprietary dataset of over 50,000 samples and 4,000 ingredients underpins an AI-powered discovery engine for identifying and optimising next-generation bioactive compounds.

API-first diagnostic infrastructure and biomarker services for healthcare companies

Hurdle is a London-based diagnostics-as-a-service company providing end-to-end diagnostic infrastructure to telehealth companies, consumer health brands, pharmaceutical companies, and clinical research organisations. Its platform integrates sample collection kit manufacturing, accredited laboratory networks, logistics, and data management tools into a single API-connected system. The company also conducts biomarker research, with published work in DNA methylation-based epigenetic biomarkers for biological age and systemic inflammation.

Next-generation sequencing and genomic analysis services

Novogene (UK) is a genomic services provider operating as the European hub of Novogene Corporation, one of the world's largest sequencing organisations. Based at Cambridge Science Park, the company offers a comprehensive range of next-generation sequencing services including whole genome, exome, RNA, single-cell, amplicon and metagenomic sequencing, supported by in-house bioinformatics analysis. Platforms include Illumina, PacBio and Oxford Nanopore technologies. Novogene serves academic research institutions, pharmaceutical companies and agricultural enterprises globally.

AI epigenomics platform for neurodegenerative disease detection

Prima Mente is a biotechnology company developing large-scale biological foundation models to understand and detect neurodegenerative disease. The company generates proprietary multi-omic data including whole-epigenome sequencing, and trains transformer-based models on DNA methylation patterns in cell-free DNA to enable non-invasive detection and molecular stratification of conditions including Alzheimer's disease and Parkinson's disease from blood samples. Its models are being validated in a longitudinal clinical study running across NHS sites in the United Kingdom.

Multi-omic sequencing and genomics services

Source Genomics is a contract genomics laboratory providing multi-omic sequencing and analytical services to pharmaceutical, biotechnology, and academic clients. Services span Sanger sequencing, next-generation sequencing, Oxford Nanopore long-read sequencing, spatial transcriptomics, optical genome mapping, Olink proteomics, epigenomics, and bioinformatics. The laboratory supports early-stage research, translational research, clinical trials, and clinical diagnostics, offering biomarker validation and assay development alongside standard sequencing workflows.

3D genomics platform for blood-based clinical diagnostics and precision medicine

Oxford BioDynamics is a biotechnology company developing blood-based diagnostic tests and precision medicine tools built on a proprietary 3D genomics platform. The platform interrogates chromosome conformation to identify epigenomic biomarkers predicting disease, prognosis, and therapeutic response. Commercial products include a blood test predicting response to immune checkpoint inhibitor therapy and a prostate cancer detection test. The company also offers an AI-driven target discovery and patient stratification tool for drug developers.

Bioinformatics CRO delivering omics data analysis and interpretation

Fios Genomics is an Edinburgh-based bioinformatics contract research organisation providing data analysis and interpretation services across genomics, transcriptomics, proteomics and metabolomics. Serving pharmaceutical, biotechnology, and academic clients globally, the company specialises in translating complex omics datasets into actionable biological insights for drug discovery, development, and applied research. With over 1,500 completed projects and 300-plus clients, Fios Genomics has strategic partnerships with Charles River Laboratories and Concept Life Sciences.

3D multi-omics platform for genetically validated drug target discovery

Enhanced Genomics is a biotechnology company developing a proprietary 3D multi-omics platform that maps genome-wide chromatin interactions to identify genetically validated drug targets for common diseases. Using patented technology integrated with a human cell type-specific multi-omics atlas, the platform links non-coding disease-associated genetic variants to causal target genes in relevant cell types. Enhanced Genomics serves pharmaceutical and biotech partners and is building an internal therapeutics pipeline focused on autoimmune conditions.